Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding

Justas V. Rodarte; Carly Baehr; Dustin Hicks; Tyler L. Liban; Connor Weidle; Peter B. Rupert; Rajwana Jahan; Abigail Wall; Andrew T. McGuire; Roland K. Strong; Scott Runyon; Marco Pravetoni; Marie Pancera

doi:10.1016/j.str.2022.11.008

Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding

Justas V. Rodarte, Carly Baehr, Dustin Hicks, Tyler L. Liban, Connor Weidle, Peter B. Rupert, Rajwana Jahan, Abigail Wall, Andrew T. McGuire, Roland K. Strong, Scott Runyon, Marco Pravetoni, Marie Pancera

Pharmacology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Opioid-related fatal overdoses have reached epidemic proportions. Because existing treatments for opioid use disorders offer limited long-term protection, accelerating the development of newer approaches is critical. Monoclonal antibodies (mAbs) are an emerging treatment strategy that targets and sequesters selected opioids in the bloodstream, reducing drug distribution across the blood-brain barrier, thus preventing or reversing opioid toxicity. We previously identified a series of murine mAbs with high affinity and selectivity for oxycodone, morphine, fentanyl, and nicotine. To determine their binding mechanism, we used X-ray crystallography to solve the structures of mAbs bound to their respective targets, to 2.2 Å resolution or higher. Structural analysis showed a critical convergent hydrogen bonding mode that is dependent on a glutamic acid residue in the mAbs’ heavy chain and a tertiary amine of the ligand. Characterizing drug-mAb complexes represents a significant step toward rational antibody engineering and future manufacturing activities to support clinical evaluation.

Original language	English (US)
Pages (from-to)	20-32.e5
Journal	Structure
Volume	31
Issue number	1
DOIs	https://doi.org/10.1016/j.str.2022.11.008
State	Published - Jan 5 2023

Bibliographical note

Funding Information:
We are particularly grateful to Julian Simon and Nick Hurlburt for their help in reviewing and preparing this paper and its figures, and to Leo Stamatatos for use of laboratory space and equipment. We are grateful to Mark LeSage for the gift of NIC311 IgG. We thank the J.B. Pendleton Charitable Trust for its generous support of Formulatrix robotic instruments. This work was funded by grants UG3 DA047711 and U01 DA051658 from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) (M. Pravetoni and M. Pancera). Some results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source, under US Department of Energy, Office of Biological and Environmental Research contract DE-AC02-06CH11357. Further work was performed at the Berkeley Center for Structural Biology, which is supported in part by the Howard Hughes Medical Institute. The Advanced Light Source is a Department of Energy Office of Science User Facility under contract no. DE-AC02-05CH11231. The Pilatus detector on 5.0.1. was funded under NIH grant S10 OD021832. The ALS-ENABLE beamlines are supported in part by the NIH, National Institute of General Medical Sciences, grant P30 GM124169. Some molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH R01 GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases. The graphical abstract was created with BioRender.com. Conceptualization, J.V.R. C.B. D.H. T.L.L. C.W. M. Pravetoni, and M. Pancera; methodology, J.V.R. C.B. D.H. T.L.L. C.W. M. Pravetoni, and M. Pancera; investigation, J.V.R. C.B. D.H. T.L.L. C.W. and A.W.; resources, C.B. D.H. R.J. S.R. and M. Pravetoni; formal analysis, J.V.R. T.L.L. C.W. and P.B.R.; writing – original draft, J.V.R and M. Pancera; writing – review and editing, J.V.R. C.B. D.H. A.T.M. R.K.S. M. Pravetoni, and M. Pancera; supervision, J.V.R. R.K.S. M. Pravetoni, and M. Pancera; funding acquisition, M. Pravetoni and M. Pancera. M. Pravetoni, D.H. and C.B. are inventors of provisional and non-provisional patent applications covering the anti-fentanyl mAbs described herein. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a gender minority in their field of research. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list.

Funding Information:
We are particularly grateful to Julian Simon and Nick Hurlburt for their help in reviewing and preparing this paper and its figures, and to Leo Stamatatos for use of laboratory space and equipment. We are grateful to Mark LeSage for the gift of NIC311 IgG. We thank the J.B. Pendleton Charitable Trust for its generous support of Formulatrix robotic instruments. This work was funded by grants UG3 DA047711 and U01 DA051658 from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) (M. Pravetoni and M. Pancera). Some results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source, under US Department of Energy , Office of Biological and Environmental Research contract DE-AC02-06CH11357 . Further work was performed at the Berkeley Center for Structural Biology, which is supported in part by the Howard Hughes Medical Institute . The Advanced Light Source is a Department of Energy Office of Science User Facility under contract no. DE-AC02-05CH11231 . The Pilatus detector on 5.0.1. was funded under NIH grant S10 OD021832 . The ALS-ENABLE beamlines are supported in part by the NIH , National Institute of General Medical Sciences , grant P30 GM124169 . Some molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH R01 GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases . The graphical abstract was created with BioRender.com .

Publisher Copyright:
© 2022 Elsevier Ltd

Keywords

crystal structure
fentanyl
ligands
mAbs
morphine
nicotine
opioid use disorder
oxycodone
vaccine

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.str.2022.11.008

Find It

Find It at U of M Libraries

Cite this

@article{0670972121734e48a84f1e882cac8cbb,

title = "Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding",

abstract = "Opioid-related fatal overdoses have reached epidemic proportions. Because existing treatments for opioid use disorders offer limited long-term protection, accelerating the development of newer approaches is critical. Monoclonal antibodies (mAbs) are an emerging treatment strategy that targets and sequesters selected opioids in the bloodstream, reducing drug distribution across the blood-brain barrier, thus preventing or reversing opioid toxicity. We previously identified a series of murine mAbs with high affinity and selectivity for oxycodone, morphine, fentanyl, and nicotine. To determine their binding mechanism, we used X-ray crystallography to solve the structures of mAbs bound to their respective targets, to 2.2 {\AA} resolution or higher. Structural analysis showed a critical convergent hydrogen bonding mode that is dependent on a glutamic acid residue in the mAbs{\textquoteright} heavy chain and a tertiary amine of the ligand. Characterizing drug-mAb complexes represents a significant step toward rational antibody engineering and future manufacturing activities to support clinical evaluation.",

keywords = "crystal structure, fentanyl, ligands, mAbs, morphine, nicotine, opioid use disorder, oxycodone, vaccine",

author = "Rodarte, {Justas V.} and Carly Baehr and Dustin Hicks and Liban, {Tyler L.} and Connor Weidle and Rupert, {Peter B.} and Rajwana Jahan and Abigail Wall and McGuire, {Andrew T.} and Strong, {Roland K.} and Scott Runyon and Marco Pravetoni and Marie Pancera",

note = "Funding Information: We are particularly grateful to Julian Simon and Nick Hurlburt for their help in reviewing and preparing this paper and its figures, and to Leo Stamatatos for use of laboratory space and equipment. We are grateful to Mark LeSage for the gift of NIC311 IgG. We thank the J.B. Pendleton Charitable Trust for its generous support of Formulatrix robotic instruments. This work was funded by grants UG3 DA047711 and U01 DA051658 from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) (M. Pravetoni and M. Pancera). Some results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source, under US Department of Energy, Office of Biological and Environmental Research contract DE-AC02-06CH11357. Further work was performed at the Berkeley Center for Structural Biology, which is supported in part by the Howard Hughes Medical Institute. The Advanced Light Source is a Department of Energy Office of Science User Facility under contract no. DE-AC02-05CH11231. The Pilatus detector on 5.0.1. was funded under NIH grant S10 OD021832. The ALS-ENABLE beamlines are supported in part by the NIH, National Institute of General Medical Sciences, grant P30 GM124169. Some molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH R01 GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases. The graphical abstract was created with BioRender.com. Conceptualization, J.V.R. C.B. D.H. T.L.L. C.W. M. Pravetoni, and M. Pancera; methodology, J.V.R. C.B. D.H. T.L.L. C.W. M. Pravetoni, and M. Pancera; investigation, J.V.R. C.B. D.H. T.L.L. C.W. and A.W.; resources, C.B. D.H. R.J. S.R. and M. Pravetoni; formal analysis, J.V.R. T.L.L. C.W. and P.B.R.; writing – original draft, J.V.R and M. Pancera; writing – review and editing, J.V.R. C.B. D.H. A.T.M. R.K.S. M. Pravetoni, and M. Pancera; supervision, J.V.R. R.K.S. M. Pravetoni, and M. Pancera; funding acquisition, M. Pravetoni and M. Pancera. M. Pravetoni, D.H. and C.B. are inventors of provisional and non-provisional patent applications covering the anti-fentanyl mAbs described herein. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a gender minority in their field of research. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. Funding Information: We are particularly grateful to Julian Simon and Nick Hurlburt for their help in reviewing and preparing this paper and its figures, and to Leo Stamatatos for use of laboratory space and equipment. We are grateful to Mark LeSage for the gift of NIC311 IgG. We thank the J.B. Pendleton Charitable Trust for its generous support of Formulatrix robotic instruments. This work was funded by grants UG3 DA047711 and U01 DA051658 from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) (M. Pravetoni and M. Pancera). Some results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source, under US Department of Energy , Office of Biological and Environmental Research contract DE-AC02-06CH11357 . Further work was performed at the Berkeley Center for Structural Biology, which is supported in part by the Howard Hughes Medical Institute . The Advanced Light Source is a Department of Energy Office of Science User Facility under contract no. DE-AC02-05CH11231 . The Pilatus detector on 5.0.1. was funded under NIH grant S10 OD021832 . The ALS-ENABLE beamlines are supported in part by the NIH , National Institute of General Medical Sciences , grant P30 GM124169 . Some molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH R01 GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases . The graphical abstract was created with BioRender.com . Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2023",

month = jan,

day = "5",

doi = "10.1016/j.str.2022.11.008",

language = "English (US)",

volume = "31",

pages = "20--32.e5",

journal = "Structure",

issn = "0969-2126",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding

AU - Rodarte, Justas V.

AU - Baehr, Carly

AU - Hicks, Dustin

AU - Liban, Tyler L.

AU - Weidle, Connor

AU - Rupert, Peter B.

AU - Jahan, Rajwana

AU - Wall, Abigail

AU - McGuire, Andrew T.

AU - Strong, Roland K.

AU - Runyon, Scott

AU - Pravetoni, Marco

AU - Pancera, Marie

N1 - Funding Information: We are particularly grateful to Julian Simon and Nick Hurlburt for their help in reviewing and preparing this paper and its figures, and to Leo Stamatatos for use of laboratory space and equipment. We are grateful to Mark LeSage for the gift of NIC311 IgG. We thank the J.B. Pendleton Charitable Trust for its generous support of Formulatrix robotic instruments. This work was funded by grants UG3 DA047711 and U01 DA051658 from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) (M. Pravetoni and M. Pancera). Some results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source, under US Department of Energy, Office of Biological and Environmental Research contract DE-AC02-06CH11357. Further work was performed at the Berkeley Center for Structural Biology, which is supported in part by the Howard Hughes Medical Institute. The Advanced Light Source is a Department of Energy Office of Science User Facility under contract no. DE-AC02-05CH11231. The Pilatus detector on 5.0.1. was funded under NIH grant S10 OD021832. The ALS-ENABLE beamlines are supported in part by the NIH, National Institute of General Medical Sciences, grant P30 GM124169. Some molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH R01 GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases. The graphical abstract was created with BioRender.com. Conceptualization, J.V.R. C.B. D.H. T.L.L. C.W. M. Pravetoni, and M. Pancera; methodology, J.V.R. C.B. D.H. T.L.L. C.W. M. Pravetoni, and M. Pancera; investigation, J.V.R. C.B. D.H. T.L.L. C.W. and A.W.; resources, C.B. D.H. R.J. S.R. and M. Pravetoni; formal analysis, J.V.R. T.L.L. C.W. and P.B.R.; writing – original draft, J.V.R and M. Pancera; writing – review and editing, J.V.R. C.B. D.H. A.T.M. R.K.S. M. Pravetoni, and M. Pancera; supervision, J.V.R. R.K.S. M. Pravetoni, and M. Pancera; funding acquisition, M. Pravetoni and M. Pancera. M. Pravetoni, D.H. and C.B. are inventors of provisional and non-provisional patent applications covering the anti-fentanyl mAbs described herein. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a gender minority in their field of research. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. Funding Information: We are particularly grateful to Julian Simon and Nick Hurlburt for their help in reviewing and preparing this paper and its figures, and to Leo Stamatatos for use of laboratory space and equipment. We are grateful to Mark LeSage for the gift of NIC311 IgG. We thank the J.B. Pendleton Charitable Trust for its generous support of Formulatrix robotic instruments. This work was funded by grants UG3 DA047711 and U01 DA051658 from the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) (M. Pravetoni and M. Pancera). Some results shown in this report are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source, under US Department of Energy , Office of Biological and Environmental Research contract DE-AC02-06CH11357 . Further work was performed at the Berkeley Center for Structural Biology, which is supported in part by the Howard Hughes Medical Institute . The Advanced Light Source is a Department of Energy Office of Science User Facility under contract no. DE-AC02-05CH11231 . The Pilatus detector on 5.0.1. was funded under NIH grant S10 OD021832 . The ALS-ENABLE beamlines are supported in part by the NIH , National Institute of General Medical Sciences , grant P30 GM124169 . Some molecular graphics and analyses were performed with UCSF ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH R01 GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases . The graphical abstract was created with BioRender.com . Publisher Copyright: © 2022 Elsevier Ltd

PY - 2023/1/5

Y1 - 2023/1/5

N2 - Opioid-related fatal overdoses have reached epidemic proportions. Because existing treatments for opioid use disorders offer limited long-term protection, accelerating the development of newer approaches is critical. Monoclonal antibodies (mAbs) are an emerging treatment strategy that targets and sequesters selected opioids in the bloodstream, reducing drug distribution across the blood-brain barrier, thus preventing or reversing opioid toxicity. We previously identified a series of murine mAbs with high affinity and selectivity for oxycodone, morphine, fentanyl, and nicotine. To determine their binding mechanism, we used X-ray crystallography to solve the structures of mAbs bound to their respective targets, to 2.2 Å resolution or higher. Structural analysis showed a critical convergent hydrogen bonding mode that is dependent on a glutamic acid residue in the mAbs’ heavy chain and a tertiary amine of the ligand. Characterizing drug-mAb complexes represents a significant step toward rational antibody engineering and future manufacturing activities to support clinical evaluation.

AB - Opioid-related fatal overdoses have reached epidemic proportions. Because existing treatments for opioid use disorders offer limited long-term protection, accelerating the development of newer approaches is critical. Monoclonal antibodies (mAbs) are an emerging treatment strategy that targets and sequesters selected opioids in the bloodstream, reducing drug distribution across the blood-brain barrier, thus preventing or reversing opioid toxicity. We previously identified a series of murine mAbs with high affinity and selectivity for oxycodone, morphine, fentanyl, and nicotine. To determine their binding mechanism, we used X-ray crystallography to solve the structures of mAbs bound to their respective targets, to 2.2 Å resolution or higher. Structural analysis showed a critical convergent hydrogen bonding mode that is dependent on a glutamic acid residue in the mAbs’ heavy chain and a tertiary amine of the ligand. Characterizing drug-mAb complexes represents a significant step toward rational antibody engineering and future manufacturing activities to support clinical evaluation.

KW - crystal structure

KW - fentanyl

KW - ligands

KW - mAbs

KW - morphine

KW - nicotine

KW - opioid use disorder

KW - oxycodone

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85145290851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85145290851&partnerID=8YFLogxK

U2 - 10.1016/j.str.2022.11.008

DO - 10.1016/j.str.2022.11.008

M3 - Article

C2 - 36513069

AN - SCOPUS:85145290851

SN - 0969-2126

VL - 31

SP - 20-32.e5

JO - Structure

JF - Structure

IS - 1

ER -

Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this